Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · February 20, 2024

Long-Term Drug Survival of Biologics in Patients With Hidradenitis Suppurativa

The British Journal of Dermatology


Additional Info

The British Journal of Dermatology
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: A Danish nationwide cohort study
Br J Dermatol 2024 Feb 02;[EPub Ahead of Print], HC Ring, J Thorsen, B Kirby, JR Ingram, NAL Rosenø, N Holgersen, VW Nielsen, D Nikolai Thein Aagaard, JT Maul, JJ Wu, JP Thyssen, A Egeberg, SF Thomsen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading